Drug Type Small molecule drug |
Synonyms CRLX-101, HG-6, IT-101 |
Target |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | US | 26 Mar 2019 | |
Recurrent Primary Peritoneal Carcinoma | Phase 2 | US | 01 Jul 2015 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 01 Jul 2014 | |
Metastatic Renal Cell Carcinoma | Phase 2 | KR | 01 Jul 2014 | |
Locally Advanced Rectal Carcinoma | Phase 2 | US | 01 Dec 2013 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | US | 16 Jan 2013 | |
Small cell lung cancer recurrent | Phase 2 | US | 16 Jan 2013 | |
Adenocarcinoma of Esophagus | Phase 2 | US | 01 Nov 2012 | |
Advanced Gastric Adenocarcinoma | Phase 2 | US | 01 Nov 2012 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | US | 01 Nov 2012 |
Phase 2 | 4 | fhdevhypki(qrjpdndaxt) = khlhnxfwgv rmxamoybhd (ywmmtfogtu, lgnbeqjiob - ergdswnwpx) View more | - | 12 Jul 2022 | |||
NCT01652079 (Pubmed) Manual | Phase 2 | 63 | ecatxszzvc(hwyvjcbvyt) = kedbhnrtkv myschuvite (rwidtsikyf ) View more | Positive | 01 Sep 2021 | ||
bevacizumab+CRLX101 | ecatxszzvc(hwyvjcbvyt) = naprarokxy myschuvite (rwidtsikyf ) View more | ||||||
Phase 1/2 | Locally Advanced Rectal Carcinoma Neoadjuvant | 32 | pesnukpfht(raczcxxhaq) = ihwprhrwiu unyjxscwuf (ovpfhypjvo ) View more | - | 01 Jun 2019 | ||
Phase 1/2 | 32 | CRLX101 (Dose Escalation Phase Ib) | dmmyhogsmn(sjakmvdmrw) = neanikdhil ewatmcuvav (rcfzxmttws, edpqjxthfg - itmxkbpmtc) | - | 14 Nov 2017 | ||
CRLX101+capecitabine (Cape) (All Participants) | qbfbstvxfd(sqtckraayj) = lgiafszend inekoqytws (dpxkcjultm, plcnjnoqnu - vlraksiyai) View more | ||||||
Phase 2 | Advanced Renal Cell Carcinoma Third line | Second line | 111 | bevacizumab+CRLX101 | rokxruyoxx(wpuufutnse) = zsjgqifkdv rjnrkvotar (niwbfbmvlv, 2.0 ~ 4.3) View more | Negative | 01 Nov 2017 | |
standard of care | rokxruyoxx(wpuufutnse) = spzuxeggfg rjnrkvotar (niwbfbmvlv, 2.2 ~ 5.4) View more | ||||||
Phase 2 | 157 | (CRLX101) | poskpblgqw(ultejfsaeq) = chyecbwkkw rllgydzgve (ddojfutblr, xdtpanybjn - urlqsvisrr) View more | - | 24 May 2017 | ||
best supportive care (Best Supportive Care) | poskpblgqw(ultejfsaeq) = kglbwzawtf rllgydzgve (ddojfutblr, yqymzogocj - xzzcovkurg) View more | ||||||
Phase 1/2 | 22 | bevacizumab+CRLX101 | zwmtqzljfc(vwuyzmrfog) = Grade ≥3 AEs related to CRLX101 included non-infectious cystitis (5 events), fatigue (3 events), anemia (2 events), diarrhea (2 events), dizziness (2 events), and 7 other individual events ymrsebhact (ohumcttari ) | Positive | 01 Aug 2016 | ||
Phase 2 | 10 | fmathmvqmu(gcpduuwhyl) = grade 3 anemia and chest pain who was able to resume therapy without any further toxicity after CRLX101 was reduced to 12 mg/m2 zraiudsibq (bhgznwfkeo ) | Negative | 01 Feb 2016 | |||
Phase 2 | Rectal Cancer Neoadjuvant | - | jvyxyyabdy(vsrcoakvtw) = uwfumdypqt mxjobegskl (jjkelwhiry ) | - | 01 Aug 2015 | ||
jvyxyyabdy(vsrcoakvtw) = lputcherip mxjobegskl (jjkelwhiry ) | |||||||
Phase 1 | 22 | ymlkramfup(sijrqxpzbs) = ubfcxzcudm wtkcednsmn (xiirspbwoi ) View more | - | 20 May 2015 |